Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Ornithine Transcarbamylase Deficiency: early-phase trial registry

4 of 5 indexed Ornithine Transcarbamylase Deficiency trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Ornithine Transcarbamylase Deficiency: 5 US clinical trials tracked, 4 recruiting.

Ornithine Transcarbamylase Deficiency is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 2 of these trials.

Enrollment posture brief

Registry condition ornithine-transcarbamylase-deficiency

OPEN 4 | RECR 80% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Ornithine Transcarbamyla (th…80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Ornithine Transcarbamylase Deficiency

Ornithine Transcarbamylase Deficiency lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ornithine Transcarbamylase Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ornithine Transcarbamylase Deficiency is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ornithine Transcarbamylase Deficiency research.

    Baylor College of Medicine accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Ornithine Transcarbamylase Deficiency trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Ornithine Transcarbamylase Deficiency research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Ornithine Transcarbamylase Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

ARCT-810 Biological
1 trials
ECUR-506 Genetic
1 trials
No Intervention Other
1 trials

US sites by state

Facility locations filed on Ornithine Transcarbamylase Deficiency trials. A trial with sites in several states counts in each.

Texas 3 trials
Colorado 2 trials
Washington 1 trials
Pennsylvania 1 trials
New York 1 trials
Maryland 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ornithine Transcarbamylase Deficiency page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Ornithine Transcarbamylase Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Baylor College of Medicine sponsors the most Ornithine Transcarbamylase Deficiency trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ornithine Transcarbamylase Deficiency condition card totals 5 registered trials; most-linked intervention ARCT-810; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.